Novel hyaluronidase variant
By modifying the structure of rHuPH20, a novel PH20 variant was designed, which solved the problems of insufficient enzyme activity and stability, improved the enzyme's thermal stability and activity, and met the application needs of the medical field.
WO2026001707A9PCT designated stage Publication Date: 2026-02-05SHANGHAI HENLIUS BIOTECH INC +2
View PDF 0 Cites 0 Cited by
Patent Information
- Application Number
- PCT/CN2025/100794
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-04-03
- Filing Date
- 2025-06-13
- Publication Date
- 2026-02-05
AI Technical Summary
Technical Problem
The existing recombinant human hyaluronidase (rHuPH20) has shortcomings in enzyme activity, thermal stability and expression efficiency, which limits its application in the medical field.
Method used
By conducting in-depth structural analysis and molecular dynamics simulations of rHuPH20, key amino acid residues were identified and modified, including N-terminal and C-terminal deletions, α-helix modifications, and single point mutations, to design novel PH20 variants that enhance enzyme activity, stability, and expression efficiency.
Benefits of technology
It achieves improved biological and physicochemical properties that enhance enzyme activity, anti-aggregation, solubility, and resistance to oxidation at high temperatures, meeting clinical needs.
✦ Generated by Eureka AI based on patent content.
Smart Images
Figure PCTCN2025100794-FTAPPB-I100001 
Figure PCTCN2025100794-FTAPPB-I100002 
Figure PCTCN2025100794-FTAPPB-I100003
Abstract
Provided is a novel hyaluronidase variant. Specifically, the present invention relates to a novel PH20 variant, a coding nucleic acid thereof, a cell comprising the coding nucleic acid, a method for producing the PH20 variant, and a pharmaceutical composition comprising the PH20 variant.
Need to check novelty before this filing date? Find Prior Art